COVID-19 infection after SARS-CoV-2 mRNA vaccination in Multiple Sclerosis, AQP4-antibody NMOSD and MOGAD patients during the Omicron subvariant BA.1/2 wave in Singapore.

Tianrong YeoRachel Wan En SiewMuhammad Yaaseen GulamJanis Siew Noi TyeAmelia Yun Yi AwThanushiree SivalingamXuejuan PengKok Pin YongSeyed Ehsan SaffariYinxia ChaoKevin Tan

Published in: Journal of neurology (2023)

The Omicron subvariant BA.1/2 is highly infectious in patients with central nervous system inflammatory diseases; three doses of mRNA vaccination improved protection. However, treatment with anti-CD20s and S1PRMs predisposed patients to earlier infection. Future studies are required to determine the protective efficacy of newer bivalent vaccines that target the Omicron (sub)variant, especially in immunocompromised patients.

Keyphrases

end stage renal disease
sars cov
multiple sclerosis
newly diagnosed
chronic kidney disease
ejection fraction
prognostic factors
peritoneal dialysis
patient reported outcomes
patient reported
respiratory failure